[go: up one dir, main page]

SI2167033T1 - Odmerna oblika, ki obsega takrolimus, za dajanje enkrat na dan - Google Patents

Odmerna oblika, ki obsega takrolimus, za dajanje enkrat na dan

Info

Publication number
SI2167033T1
SI2167033T1 SI200831836T SI200831836T SI2167033T1 SI 2167033 T1 SI2167033 T1 SI 2167033T1 SI 200831836 T SI200831836 T SI 200831836T SI 200831836 T SI200831836 T SI 200831836T SI 2167033 T1 SI2167033 T1 SI 2167033T1
Authority
SI
Slovenia
Prior art keywords
tacrolimus
dosage form
oral dosage
once daily
daily oral
Prior art date
Application number
SI200831836T
Other languages
English (en)
Inventor
Per Holm
Tomas Norling
Anne-Marie Lademann
Original Assignee
Veloxis Pharmaceuticals A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39766919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2167033(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Veloxis Pharmaceuticals A/S filed Critical Veloxis Pharmaceuticals A/S
Publication of SI2167033T1 publication Critical patent/SI2167033T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SI200831836T 2007-05-30 2008-05-30 Odmerna oblika, ki obsega takrolimus, za dajanje enkrat na dan SI2167033T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200700783 2007-05-30
DKPA200701573 2007-11-07
PCT/DK2008/050130 WO2008145143A1 (en) 2007-05-30 2008-05-30 Once daily oral dosage form comprising tacrolimus
EP08748829.2A EP2167033B1 (en) 2007-05-30 2008-05-30 Once daily oral dosage form comprising tacrolimus

Publications (1)

Publication Number Publication Date
SI2167033T1 true SI2167033T1 (sl) 2017-08-31

Family

ID=39766919

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200831836T SI2167033T1 (sl) 2007-05-30 2008-05-30 Odmerna oblika, ki obsega takrolimus, za dajanje enkrat na dan

Country Status (10)

Country Link
US (7) US8685998B2 (sl)
EP (1) EP2167033B1 (sl)
CA (1) CA2688381C (sl)
DK (1) DK2167033T3 (sl)
ES (1) ES2634153T3 (sl)
HU (1) HUE033011T2 (sl)
LT (1) LT2167033T (sl)
PL (1) PL2167033T4 (sl)
SI (1) SI2167033T1 (sl)
WO (1) WO2008145143A1 (sl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020994A1 (en) 2003-08-29 2005-03-10 Lifecycle Pharma A/S Solid dispersions comprising tacrolimus
RS52672B2 (sr) 2006-08-03 2018-03-30 Horizon Pharma Ag Tretman reumatoidnih bolesti glukokortikoidom sa odloženim-oslobađanjem
SI2167033T1 (sl) 2007-05-30 2017-08-31 Veloxis Pharmaceuticals A/S Odmerna oblika, ki obsega takrolimus, za dajanje enkrat na dan
US12083103B2 (en) 2007-05-30 2024-09-10 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
WO2009080030A1 (en) * 2007-12-21 2009-07-02 Lifecycle Pharma A/S Treatment of autoimmune hepatitis with a once daily oral dosage form comprising tacrolimus
CA2749646A1 (en) * 2009-01-26 2010-07-29 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
US10813917B2 (en) 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
PT2575769T (pt) 2010-02-17 2016-09-22 Veloxis Pharmaceuticals As Composição de tacrolímus estabilizada
US20120072231A1 (en) * 2010-09-22 2012-03-22 I.D. Therapeutics Llc Methods, systems, and apparatus for optimizing effects of treatment with medication using medication compliance patterns
US20120203573A1 (en) 2010-09-22 2012-08-09 I.D. Therapeutics Llc Methods, systems, and apparatus for optimizing effects of treatment with medication using medication compliance patterns
EP2589383A1 (en) * 2011-11-06 2013-05-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin FKBP subtype-specific rapamycin analogue for use in treatment of diseases
FR2986532B1 (fr) * 2012-02-07 2015-03-13 Polymerexpert Sa Compositions polymeres metastables pour dispositifs d'injection d'implants ophtalmiques
DK3030232T3 (da) 2013-04-29 2022-10-10 Medregen Llc Sårheling via autolog stamecellemobilisering
US9168246B2 (en) 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
CN107949388B (zh) 2015-10-09 2021-10-26 艾森医药公司 吡咯并嘧啶激酶抑制剂的药用盐、物理形态和组合物及其制备方法
GB201600376D0 (en) 2016-01-08 2016-02-24 Chronos Therapeutics Ltd Novel therapeutic agents
WO2022187379A1 (en) 2021-03-03 2022-09-09 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions
CN114469847B (zh) * 2021-12-29 2024-08-13 北京鑫开元医药科技有限公司 他克莫司栓剂及其制备方法和用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB8608080D0 (en) 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
KR0177158B1 (ko) 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
JP3520517B2 (ja) 1992-11-18 2004-04-19 藤沢薬品工業株式会社 医薬用持続性製剤
US6204243B1 (en) * 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
TW426516B (en) 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
TW450810B (en) 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
CA2322516C (en) 1998-03-26 2010-10-05 Fujisawa Pharmaceutical Co., Ltd. Sustained release macrolide compositions
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6168806B1 (en) 1999-03-05 2001-01-02 Fang-Yu Lee Orally administrable nifedipine pellet and process for the preparation thereof
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB0007842D0 (en) 2000-03-31 2000-05-17 Spruce Barbara Sigma receptor ligands and their medical uses
EP1275373A4 (en) 2000-04-17 2007-04-04 Astellas Pharma Inc DRUG DISPERSION SYSTEM FOR THE AVOIDANCE OF PHARMACOKINETIC INTERACTIONS BETWEEN ACTIVE SUBSTANCES AND METHODOLOGY THEREOF
US6761895B2 (en) * 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
US20020028240A1 (en) 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
JP2004503511A (ja) 2000-06-12 2004-02-05 スミスクライン・ビーチャム・コーポレイション 新規固体分散剤組成物
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US7217431B2 (en) 2001-07-06 2007-05-15 Lifecycle Pharma A/S Controlled agglomeration
WO2005004848A1 (en) 2003-07-09 2005-01-20 Chong Kun Dang Pharmaceutical Corp. The solid dispersion of tacrolimus
ES2376238T3 (es) * 2003-08-29 2012-03-12 Veloxis Pharmaceuticals A/S Composiciones de liberación modificada comprendiendo tacrolimus.
WO2005020994A1 (en) 2003-08-29 2005-03-10 Lifecycle Pharma A/S Solid dispersions comprising tacrolimus
EP1675576A1 (en) 2003-10-03 2006-07-05 LifeCycle Pharma A/S A method for preparing modified release pharmaceutical compositions
NO320286B1 (no) 2003-11-19 2005-11-21 Dag Herman Zeiner-Gundersen Turbin for kraftproduksjon
US20050249799A1 (en) 2004-03-03 2005-11-10 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
EA011244B1 (ru) 2004-03-18 2009-02-27 Панацея Биотек Лтд. Новые композиции для местной доставки
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
KR20070116581A (ko) 2004-12-15 2007-12-10 엘란 파마 인터내셔널 리미티드 나노입자형 타크롤리무스 제제
KR100678824B1 (ko) 2005-02-04 2007-02-05 한미약품 주식회사 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
BRPI0606282A2 (pt) 2005-03-17 2009-06-09 Elan Pharma Int Ltd composições injetáveis de compostos imunossupressores em nanopartìculas
EP1896075A2 (en) 2005-06-22 2008-03-12 LifeCycle Pharma A/S Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor
KR100693461B1 (ko) 2005-07-29 2007-03-12 동국제약 주식회사 마크로라이드계 항생물질을 유효성분으로 함유하는약제학적 조성물 및 이의 제조방법과, 상기 약제학적조성물을 함유하는 서방성 제제
JP2008037808A (ja) 2006-08-07 2008-02-21 Astellas Pharma Inc タクロリムスカプセル剤
EP2067475A4 (en) * 2006-09-26 2010-12-15 Astellas Pharma Inc PREPARATION FOR TACROLIMUS MAINTAINED RELEASE
UA93148C2 (ru) * 2007-03-29 2011-01-10 Панасэа Биотэк Лимитэд Дозированная форма тароликмуса модифицированного высвобождения
SI2167033T1 (sl) 2007-05-30 2017-08-31 Veloxis Pharmaceuticals A/S Odmerna oblika, ki obsega takrolimus, za dajanje enkrat na dan

Also Published As

Publication number Publication date
US20210046055A1 (en) 2021-02-18
US8685998B2 (en) 2014-04-01
US11110081B2 (en) 2021-09-07
EP2167033B1 (en) 2017-04-19
US20110275659A1 (en) 2011-11-10
US11123331B2 (en) 2021-09-21
US20100105717A1 (en) 2010-04-29
HUE033011T2 (hu) 2017-11-28
EP2167033A1 (en) 2010-03-31
PL2167033T3 (pl) 2017-12-29
PL2167033T4 (pl) 2018-08-31
US20140179731A1 (en) 2014-06-26
CA2688381A1 (en) 2008-12-04
US8664239B2 (en) 2014-03-04
WO2008145143A1 (en) 2008-12-04
LT2167033T (lt) 2017-08-10
ES2634153T3 (es) 2017-09-26
CA2688381C (en) 2016-10-11
US20210046054A1 (en) 2021-02-18
DK2167033T3 (en) 2017-08-14
US10864199B2 (en) 2020-12-15
US20120029009A1 (en) 2012-02-02
US20160243091A1 (en) 2016-08-25

Similar Documents

Publication Publication Date Title
PL2167033T4 (pl) Podawana raz dziennie doustna postać dawkowania zawierająca takrolimus
IL206159A0 (en) Oral pharmaceutical dosage forms
PT2077729E (pt) Formas orais probióticas
SI2384754T1 (sl) farmacevtske odmerne oblike
IL205160A0 (en) Oral dosage forms comprising licarbazepine acetate
ZA201006029B (en) Pharmaceutical dosage form
PT2361081T (pt) Forma de dosagem intra-oral multiporção e seu uso
GB0710439D0 (en) Oral dosage form
ZA200903858B (en) Pharmaceutical dosage form
IL200619A0 (en) Novel dosage form
GB0721332D0 (en) Medicaments
GB0616794D0 (en) Solid dosage form
EP2114418A4 (en) ORAL DOSAGE FORM WITH STABILIZED PICOPLATIN
GB0625783D0 (en) Medicament
GB0822124D0 (en) Oral dosage form
PL2008940T3 (pl) Butelka dozująca
GB0615064D0 (en) Medicament
GB0717450D0 (en) Medicament
LT2174652T (lt) Peroralinės farmacinės desmopresino kompozicijos
GB0721333D0 (en) Medicaments
GB0615814D0 (en) Medicament
ZA200708369B (en) Medicament
GB0704123D0 (en) Dosage form
HK1133593A (en) Oral cephalotaxine dosage forms